The Alphabet, Astellas, Novartis and WuXi AppTec-backed cancer therapy developer priced its shares at the foot of their range in an upsized offering.
TScan Therapeutics, the US-based cancer immunotherapy developer which counts internet and technology group Alphabet and pharmaceutical firms Astellas, Novartis and WuXi AppTec as investors, secured $100m in its initial public offering on Friday.
The company issued almost 6.7 million shares on the Nasdaq Global Market priced at $15 each having set a range of $15 to $17 for 6.3 million shares. They closed at $10.50 on the the company’s first day of trading.
Founded in 2018, TScan is working on…
